person · Reporting owner

Martini Jeffrey S

Disclosed activity across 1 company

Tapewire entity: 67185
SEC CIK: 0001914560

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
PALVELLA THERAPEUTICS, INC.PVLA · Entity 4452	Chief Scientific Officer	February 05, 2026	February 09, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

PALVELLA THERAPEUTICS, INC.

Report date February 05, 2026 · Filed February 09, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $76.43 · Expires 2036-02-05	Direct	64,318	Reported balance After 2026-02-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-02-05 · Grant · Acquired 64,318 · Balance 64,318 F1: The shares subject to this option shall vest and become exercisable in equal monthly installments over 48 months commencing from February 5, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to this option shall vest and become exercisable in equal monthly installments over 48 months commencing from February 5, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 05, 2026 Filed Feb 9, 2026 21:08 UTC	PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452	GrantStock Option (Right to Buy) · Derivative	64,318	$0.00 Strike: $76.43	$0.00	Disclosure SEC source: 0001104659-26-012068 · tm265512-5_4seq1.xml · derivative · entry 1 Martini Jeffrey S · CIK 0001914560 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,318 Underlying: Common Stock · 64,318 shares Expires 2036-02-05 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in equal monthly installments over 48 months commencing from February 5, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document
February 05, 2025 Filed Feb 10, 2025 23:00 UTC Amendment	PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452	GrantNon-Qualified Stock Option (right to buy) · Derivative	123,559	$0.00 Strike: $14.76	$0.00	Disclosure SEC source: 0001583648-25-000021 · edgardoc.xml · derivative · entry 2 Martini Jeffrey S · CIK 0001914560 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,559 Underlying: Common Stock · 123,559 shares Expires 2035-02-05 F1 · derivative.exercise_date: The stock options will vest in equal monthly tranches over 48 months Read SEC document
February 05, 2025 Filed Feb 10, 2025 23:00 UTC Amendment	PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452	GrantIncentive Stock Option (right to buy) · Derivative	5,373	$0.00 Strike: $14.76	$0.00	Disclosure SEC source: 0001583648-25-000021 · edgardoc.xml · derivative · entry 1 Martini Jeffrey S · CIK 0001914560 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,373 Underlying: Common Stock · 5,373 shares Expires 2035-02-05 F1 · derivative.exercise_date: The stock options will vest in equal monthly tranches over 48 months Read SEC document
December 13, 2024 Filed Dec 18, 2024 01:44 UTC	PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452	GrantStock Option (right to buy) · Derivative	126,416	$0.00 Strike: $13.60	$0.00	Disclosure SEC source: 0001062993-24-020820 · form4.xml · derivative · entry 1 Martini Jeffrey S · CIK 0001914560 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,416 Underlying: Common Stock · 126,416 shares Expires 2034-12-13 F1 · derivative.exercise_date: The stock options will vest in equal monthly tranches over 48 months. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.